Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Raras (9)

2023

  1. A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

    Blood, Vol. 142, Núm. 20, pp. 1752-1756

  2. Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL

    British Journal of Haematology

  3. Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma

    Nature Communications, Vol. 14, Núm. 1

2022

  1. OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells

    Frontiers in Oncology, Vol. 12

2021

  1. Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects

    Scientific Reports, Vol. 11, Núm. 1

  2. Targeting OGG1 arrests cancer cell proliferation by inducing replication stress

    Nucleic Acids Research, Vol. 48, Núm. 21, pp. 12234-12251

2020

  1. Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL

    Blood, Vol. 136, Núm. 3, pp. 313-327

2018

  1. Gain-of-function mutations in DNMT3A in patients with paraganglioma

    Genetics in Medicine, Vol. 20, Núm. 12, pp. 1644-1651

2017

  1. Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients

    EMBO Molecular Medicine, Vol. 9, Núm. 11, pp. 1574-1588